Skip to main content

Solid Biosciences Inc.

corporate_fare Company Profile

Solid Biosciences Inc.

SLDB·NASDAQ·Life Sciences·CIK 0001707502

Solid Biosciences Inc. is a life sciences company dedicated to developing gene therapy candidates for genetic neuromuscular and cardiac diseases. The company's portfolio includes SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich's ataxia, SGT-501 for Catecholaminergic polymorphic ventricular tachycardia, and SGT-601 for TNNT2-mediated dilated cardiomyopathy. These candidates are at various stages of development with different investment levels. Solid Biosciences focuses on rare neuromuscular and cardiac diseases, integrating internal capabilities such as a vector core, validated animal models, optimized expression cassettes, novel capsids, and regulatory expertise. The company also collaborates with leaders in clinical and research fields. Its business model prioritizes identifying and developing therapies for underserved patients with potentially fatal neuromuscular and cardiac diseases, building innovative libraries of delivery capsids and other enabling technologies, and collaborating with leading experts in the field. The company's mission is to treat and change the course of neuromuscular and cardiac diseases at all stages.

Solid Biosciences Inc. (NASDAQ:SLDB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for SLDB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for SLDB spans 10-Q, SCHEDULE 13D/A, 8-K, PRE 14A.

Recent high-impact activity:

  • Solid Bio Posts $53.9M Q3 Loss, Sets Late-Q4 FDA Meeting on Duchenne Gene Therapy
  • Solid Biosciences Q3 Loss Widens to $53.9M; $348.9M Cash Funds Runway Into 1H 2028
  • Perceptive Advisors Lifts Solid Biosciences Stake to 11.2% with $0.001 Pre-Funded Warrants
  • Solid Biosciences Replaces Exhausted $85M ATM with New $200M Equity Program
  • Solid Biosciences Q2 Loss Widens to $54.8M, Cash Runway Extended to Mid-2028

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$174.32M
Diluted EPS
-$1.99
Op. Cash Flow
-$156.29M
Free Cash Flow
-$157.44M
Operating Income
-$179.21M
Cash & Equivalents
$59.9M
Debt / Equity
0.00×
Shares Outstanding
78.97M sh
Source: 10-K · filed 2026-03-19 · accession 0001193125-26-115928

Short Interest & Short Volume

10.71 days to cover

FINRA reported short interest of 13,303,890 shares in SLDB as of the October 30, 2026 settlement, a 8.2% increase from the prior period — about 10.7 days to cover at its recent average daily volume. On November 20, 2026, 71.4% of SLDB volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)13,303,890 shares as of October 30, 2026
Change vs prior period▲ 8.2%
Days to cover10.71 at avg daily volume of 1,242,093
Daily short volume (FINRA facilities)71.4% of 451,783 shares on November 20, 2026
5-day average short volume67.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for SLDB, detected from its recent SEC filings · based on capital-structure filings through 2026-08-06.

1 recent capital raiseATM program1 shelf registration

New $200M ATM Program Established · Prior $85M ATM Fully Drawn

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with S →
$6.25
52-week range · as of 2026-11-04 $3.79 – $11.45
Market cap
$697.57M
Volume
1.6M (1.1× avg)
3-mo avg 1.4M
Live data · 2026-11-22 12:40 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SLDB - Latest Insights

SLDB
Nov 04, 2026, 4:07 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $6.52
Real-time Price: $6.25 info
Change: -$0.270 (-4%) info
Market Cap: $697.566M info
SLDB
Nov 04, 2026, 4:02 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $6.52
Real-time Price: $6.25 info
Change: -$0.270 (-4%) info
Market Cap: $697.566M info
SLDB
Aug 14, 2026, 5:22 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $9.38
Real-time Price: $6.25 info
Change: -$3.13 (-33%) info
Market Cap: $697.566M info
SLDB
Aug 06, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.25
Real-time Price: $6.25 info
Change: -$2.00 (-24%) info
Market Cap: $697.566M info
SLDB
Aug 06, 2026, 4:23 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $8.65
Real-time Price: $6.25 info
Change: -$2.40 (-28%) info
Market Cap: $697.566M info
SLDB
Jun 24, 2026, 6:49 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $9.29
Real-time Price: $6.25 info
Change: -$3.04 (-33%) info
Market Cap: $697.566M info
SLDB
Jun 10, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.61
Real-time Price: $6.25 info
Change: -$0.360 (-5%) info
Market Cap: $697.566M info
SLDB
Jun 02, 2026, 7:15 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $7.43
Real-time Price: $6.25 info
Change: -$1.18 (-16%) info
Market Cap: $697.566M info
SLDB
May 12, 2026, 4:02 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $7.72
Real-time Price: $6.25 info
Change: -$1.47 (-19%) info
Market Cap: $697.566M info
SLDB
May 07, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $6.91
Real-time Price: $6.25 info
Change: -$0.660 (-10%) info
Market Cap: $697.566M info
SLDB
Apr 30, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.12
Real-time Price: $6.25 info
Change: -$0.870 (-12%) info
Market Cap: $697.566M info
SLDB
Apr 10, 2026, 4:10 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $8.02
Real-time Price: $6.25 info
Change: -$1.77 (-22%) info
Market Cap: $697.566M info
SLDB
Mar 19, 2026, 5:04 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $7.12
Real-time Price: $6.25 info
Change: -$0.870 (-12%) info
Market Cap: $697.566M info
SLDB
Mar 19, 2026, 5:03 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $7.12
Real-time Price: $6.25 info
Change: -$0.870 (-12%) info
Market Cap: $697.566M info
SLDB
Mar 19, 2026, 4:01 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $7.12
Real-time Price: $6.25 info
Change: -$0.870 (-12%) info
Market Cap: $697.566M info
SLDB
Mar 17, 2026, 6:50 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $7.80
Real-time Price: $6.25 info
Change: -$1.55 (-20%) info
Market Cap: $697.566M info
SLDB
Mar 11, 2026, 5:34 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $7.85
Real-time Price: $6.25 info
Change: -$1.60 (-20%) info
Market Cap: $697.566M info
SLDB
Mar 11, 2026, 4:00 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $8.16
Real-time Price: $6.25 info
Change: -$1.91 (-23%) info
Market Cap: $697.566M info
SLDB
Mar 11, 2026, 1:02 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $7.51
Real-time Price: $6.25 info
Change: -$1.26 (-17%) info
Market Cap: $697.566M info
SLDB
Mar 10, 2026, 5:00 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $8.23
Real-time Price: $6.25 info
Change: -$1.98 (-24%) info
Market Cap: $697.566M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets